New medications that spur weight loss and take care of diabetes have been taking the general public—and the pharmaceutical field—by storm. The newest entrant, Zepbound, a short while ago joined Ozempic, Wegovy, Victoza and Other individuals inside of a escalating course of prescription drugs known as GLP-one receptor agonists.In 2005 a syntheti